PE20131140A1 - Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos - Google Patents
Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usosInfo
- Publication number
- PE20131140A1 PE20131140A1 PE2013000110A PE2013000110A PE20131140A1 PE 20131140 A1 PE20131140 A1 PE 20131140A1 PE 2013000110 A PE2013000110 A PE 2013000110A PE 2013000110 A PE2013000110 A PE 2013000110A PE 20131140 A1 PE20131140 A1 PE 20131140A1
- Authority
- PE
- Peru
- Prior art keywords
- galns
- enzyme
- column
- sulfatase
- acetylgalactosamine
- Prior art date
Links
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 101710099863 N-acetylgalactosamine-6-sulfatase Proteins 0.000 title 1
- 101001066305 Homo sapiens N-acetylgalactosamine-6-sulfatase Proteins 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 2
- 230000000717 retained effect Effects 0.000 abstract 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 abstract 1
- 208000025797 Mucopolysaccharidosis type 4A Diseases 0.000 abstract 1
- 102000005262 Sulfatase Human genes 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 102000049489 human GALNS Human genes 0.000 abstract 1
- 102000046949 human MSC Human genes 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 108060007951 sulfatase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN PROCESO DE PRODUCCION DE UNA N-ACETILGALACTOSAMINA-6-SULFATASA HUMANA (GALNS), ACTIVA ALTAMENTE FOSFORILADA QUE COMPRENDE: A) FILTRACION DE UN MEDIO DE CULTIVO DE LA ENZIMA GALNS SECRETADA POR UNA LINEA DE CELULAS MAMIFERAS QUE EXPRESA EL FACTOR HUMANO 1 MODIFICADOR DE LAS SULFATASAS ( SUMF 1) Y LA ENZIMA GALNS HUMANA RECOMBINANTE UTILIZANDO CARBON ACTIVADO ; B) SE COLOCA EL FILTRADO ANTERIOR EN UNA COLUMNA DE CAPTURA BAJO CONDICIONES TALES QUE LA ENZIMA GALNS QUEDE RETENIDA EN LA COLUMNA; C) SE AJUSTA EL PH DEL PRODUCTO DE LA FILTRACION DEL PASO B) HASTA ALCANZAR UN PH DE 4,5±0,1; D) COLOCAR EL PRODUCTO ANTERIOR EN UNA COLUMNA DE INTERCAMBIO IONICO, REALIZAR EL LAVADO BAJO CONDICIONES ADECUADAS TALES QUE LA ENZIMA GALNS QUEDE RETENIDA EN LA COLUMA.DICHO PROCESO TIENE UNA PUREZA DE 95% Y EL97% DE LA ENZIMA GALNS SE ENCUENTRA EN LA FORMA DEL PRECURSOR. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA.DICHO PROCESO ES UTIL PARA EL TRATAMIENTO DE MUCOPOLISACARIDOSIS TIPO IVa (MPS IVa).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36671410P | 2010-07-22 | 2010-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131140A1 true PE20131140A1 (es) | 2013-10-17 |
Family
ID=44543776
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001625A PE20171798A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
| PE2013000110A PE20131140A1 (es) | 2010-07-22 | 2011-07-22 | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| PE2017001626A PE20171799A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001625A PE20171798A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001626A PE20171799A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8765437B2 (es) |
| EP (1) | EP2595650B1 (es) |
| JP (2) | JP6030553B2 (es) |
| KR (2) | KR101598897B1 (es) |
| CN (1) | CN103037895B (es) |
| AR (2) | AR082319A1 (es) |
| AU (1) | AU2011280937B2 (es) |
| BR (1) | BR112013001558B1 (es) |
| CA (2) | CA3146151A1 (es) |
| CL (2) | CL2013000219A1 (es) |
| CY (1) | CY1118934T1 (es) |
| DK (1) | DK2595650T3 (es) |
| ES (1) | ES2616263T3 (es) |
| HR (1) | HRP20170245T1 (es) |
| HU (1) | HUE033163T2 (es) |
| IL (2) | IL224125B (es) |
| LT (1) | LT2595650T (es) |
| MX (1) | MX341838B (es) |
| PE (3) | PE20171798A1 (es) |
| PL (1) | PL2595650T3 (es) |
| PT (1) | PT2595650T (es) |
| RS (1) | RS55669B1 (es) |
| RU (1) | RU2607376C2 (es) |
| SG (1) | SG187580A1 (es) |
| SI (1) | SI2595650T1 (es) |
| SM (2) | SMT201700106T1 (es) |
| WO (1) | WO2012012718A2 (es) |
| ZA (1) | ZA201300286B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2711590C (en) * | 2008-01-18 | 2021-03-23 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| US20130202633A1 (en) * | 2012-02-07 | 2013-08-08 | Saint Louis University, A Non-Profit Organization | Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US11529397B2 (en) | 2018-01-22 | 2022-12-20 | Saint Louis University | Method of treating mucopolysaccharidosis type IVA |
| DK2968494T3 (en) * | 2013-03-13 | 2019-03-04 | Seattle Genetics Inc | ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs |
| JP2016518113A (ja) * | 2013-03-13 | 2016-06-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | リソソーム系酵素の特性評価の方法 |
| CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| WO2014201220A1 (en) * | 2013-06-12 | 2014-12-18 | The Board Of Trustees Of The University Of Illinois | Methods for detecting prostate cancer |
| US9910041B2 (en) | 2013-07-12 | 2018-03-06 | Emd Millipore Corporation | Method of determining virus removal from a sample containing a target protein using activated carbon |
| EP3166626B1 (en) * | 2014-07-11 | 2021-04-28 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
| US10472615B2 (en) | 2016-01-21 | 2019-11-12 | Saint Louis University | Reduced immunogenic proteins for lysosomal storage disorders |
| JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール．ピー．シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
| EP3676375A4 (en) * | 2017-08-31 | 2021-04-07 | Green Cross Corporation | PROCESS FOR PURIFYING A SULFATASE PROTEIN |
| MX2020012911A (es) * | 2018-05-30 | 2021-02-26 | Esteve Pharmaceuticals Sa | Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a. |
| RU2763990C2 (ru) * | 2020-02-19 | 2022-01-12 | Акционерное общество "ГЕНЕРИУМ" | Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки |
| US20230193205A1 (en) * | 2020-04-19 | 2023-06-22 | Figene, Llc | Gene modified fibroblasts for therapeutic applications |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| TW202403043A (zh) * | 2022-03-18 | 2024-01-16 | 美商健臻公司 | 重組人類酸性鞘磷脂酶醫藥組合物及方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| JPS62122588A (ja) | 1985-11-22 | 1987-06-03 | Taiyo Fishery Co Ltd | 純コンドロイチナ−ゼの製造法 |
| US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US7083793B2 (en) | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| RU2195492C2 (ru) * | 2000-09-04 | 2002-12-27 | Институт физиологии Коми научного центра Уральского отделения РАН | Способ получения пектолитического ферментного препарата |
| DK1395669T3 (da) | 2001-01-26 | 2009-11-16 | Selexis Sa | Matriks bindingsregioner og fremgangsmåder til anvendelse af disse |
| US7332304B2 (en) * | 2002-07-01 | 2008-02-19 | Arkion Life Sciences Llc | Process and materials for production of glucosamine and N-acetylglucosamine |
| CA2515708A1 (en) | 2003-02-11 | 2004-08-26 | Transkaryotic Therapies, Inc. | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies |
| JP2007277094A (ja) * | 2004-06-29 | 2007-10-25 | Chemo Sero Therapeut Res Inst | 改変ダニ主要アレルゲン含有医薬組成物 |
| EP1836316A4 (en) * | 2004-12-22 | 2009-07-22 | Ambrx Inc | PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE |
| AU2007240732B2 (en) * | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| US20080231439A1 (en) | 2007-03-22 | 2008-09-25 | Inventec Corporation | Activity Detection Circuit for a Storage Device |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| CA2711590C (en) * | 2008-01-18 | 2021-03-23 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
-
2011
- 2011-07-21 AR ARP110102649A patent/AR082319A1/es not_active Application Discontinuation
- 2011-07-22 CA CA3146151A patent/CA3146151A1/en active Pending
- 2011-07-22 PE PE2017001625A patent/PE20171798A1/es unknown
- 2011-07-22 WO PCT/US2011/045011 patent/WO2012012718A2/en not_active Ceased
- 2011-07-22 HU HUE11751689A patent/HUE033163T2/en unknown
- 2011-07-22 PE PE2013000110A patent/PE20131140A1/es not_active Application Discontinuation
- 2011-07-22 SG SG2013004841A patent/SG187580A1/en unknown
- 2011-07-22 LT LTEP11751689.8T patent/LT2595650T/lt unknown
- 2011-07-22 AU AU2011280937A patent/AU2011280937B2/en active Active
- 2011-07-22 EP EP11751689.8A patent/EP2595650B1/en active Active
- 2011-07-22 SM SM20170106T patent/SMT201700106T1/it unknown
- 2011-07-22 PE PE2017001626A patent/PE20171799A1/es unknown
- 2011-07-22 PL PL11751689T patent/PL2595650T3/pl unknown
- 2011-07-22 KR KR1020137004487A patent/KR101598897B1/ko active Active
- 2011-07-22 MX MX2013000908A patent/MX341838B/es active IP Right Grant
- 2011-07-22 BR BR112013001558-6A patent/BR112013001558B1/pt active IP Right Grant
- 2011-07-22 DK DK11751689.8T patent/DK2595650T3/en active
- 2011-07-22 RS RS20170165A patent/RS55669B1/sr unknown
- 2011-07-22 KR KR1020157007141A patent/KR101949906B1/ko active Active
- 2011-07-22 CN CN201180035900.4A patent/CN103037895B/zh active Active
- 2011-07-22 PT PT117516898T patent/PT2595650T/pt unknown
- 2011-07-22 JP JP2013520881A patent/JP6030553B2/ja active Active
- 2011-07-22 HR HRP20170245TT patent/HRP20170245T1/hr unknown
- 2011-07-22 CA CA2805673A patent/CA2805673C/en active Active
- 2011-07-22 RU RU2013107765A patent/RU2607376C2/ru active
- 2011-07-22 SI SI201131104A patent/SI2595650T1/sl unknown
- 2011-07-22 ES ES11751689.8T patent/ES2616263T3/es active Active
- 2011-07-22 US US13/188,907 patent/US8765437B2/en active Active
-
2013
- 2013-01-07 IL IL224125A patent/IL224125B/en active IP Right Grant
- 2013-01-11 ZA ZA2013/00286A patent/ZA201300286B/en unknown
- 2013-01-22 CL CL2013000219A patent/CL2013000219A1/es unknown
-
2014
- 2014-05-19 US US14/281,538 patent/US8940513B2/en active Active
- 2014-12-17 US US14/573,907 patent/US9567572B2/en active Active
-
2016
- 2016-07-15 JP JP2016140213A patent/JP2016178950A/ja not_active Withdrawn
-
2017
- 2017-02-15 CY CY20171100207T patent/CY1118934T1/el unknown
- 2017-02-16 SM SM201700106T patent/SMT201700106B/it unknown
- 2017-03-02 CL CL2017000498A patent/CL2017000498A1/es unknown
-
2018
- 2018-06-26 IL IL260282A patent/IL260282B/en active IP Right Grant
-
2020
- 2020-07-31 AR ARP200102165A patent/AR119552A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131140A1 (es) | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos | |
| PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| PH12019500398A1 (en) | Transcription factor nterf241 and methods of using the same | |
| MX340718B (es) | Proceso y sistema para obtener neurotoxina botulinica. | |
| EA201171285A1 (ru) | Новая технология изготовления диклофенака | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| FR2896511B1 (fr) | Procede de culture de cellules issues du tissu adipeux et leurs applications. | |
| EA201171286A1 (ru) | Новая технология изготовления индометацина | |
| MX2012008932A (es) | Proceso para la integracion de calor para la produccion de etanol y proceso de purificacion. | |
| EA201171283A1 (ru) | Новая технология изготовления мелоксикама | |
| HK1207308A1 (en) | Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules | |
| MY172577A (en) | Method for producing alcohol from cellulose-containing biomass | |
| WO2012083089A3 (en) | Apparatus and methods for disinfecting contact lenses | |
| BR112014017215B8 (pt) | Método para produzir um produto químico | |
| AU2012297573A8 (en) | Method for the recovery of magnesium sulphate and production of magnesium oxide | |
| WO2012160360A3 (en) | Photosynthetic process | |
| CO6290749A2 (es) | Un proceso para aumentar la concentracion de colonias de microorganismos en un proceso de remocion de impurezas por sdigestion anaerobica | |
| CN101066907A (zh) | 医用甘油的提炼 | |
| RU2014107682A (ru) | Способ получения миобластов, использование биоптата десны, препарат миобластов для лечения патологий мышечной ткани и способ его получения | |
| RU2011151959A (ru) | Способ приготовления электроактивированной воды | |
| WO2014020517A3 (en) | Production of extracellular tyrosinase enzyme using the fungus gliocephalotrichum for various applications | |
| CN104130340A (zh) | 一种利用鸭胸骨制备硫酸软骨素的制备方法 | |
| FI20115497A7 (fi) | Menetelmä ja laitteisto hydroksikarboksyylihappotuotteen erottamiseksi | |
| MD4078C1 (ro) | Procedeu de fabricare a vinului din materie primă cu aciditate majorată |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |